OmanDocSign in

Curriculum · Public Health and Communicable Diseases

Latent tuberculosis and tuberculin skin testing

What it is

The diagnosis of latent TB infection involves demonstration of immune memory to mycobacterial proteins. Two tests are available for that: the tuberculin skin test and interferon-gamma release assays.

How it is diagnosed

The Mantoux skin test consists of an intradermal injection of one-tenth of a milliliter of PPD tuberculin and represents delayed type hypersensitivity. The size of induration is measured 48-72 hours later; erythema, that is redness, should not be measured. A positive result is a delayed hypersensitivity reaction evident 48-72 hours after the intradermal injection of purified protein derivative, giving a raised indurated lesion above 6 mm in diameter in nonvaccinated adults, or above 15 mm in BCG-vaccinated adults.

False negative, anergic, skin tests occur with immunosuppression due to HIV infection with CD4+ below 200/mm3, in sarcoidosis, with drugs such as chemotherapy, anti-TNF therapy and steroids, and through cross-reactivity with non-tuberculous mycobacteria and BCG vaccination. The skin test is also written down as having low sensitivity and specificity, useful only in primary or deep-seated infection.

These limitations may be overcome by interferon-gamma release assays. They detect T-cell secretion of interferon-gamma following exposure to M tuberculosis-specific antigens, ESAT-6 and CFP-10. A sample of either purified T cells or whole blood is incubated in the presence of antigens specific to Mycobacterium tuberculosis, and the release of interferon-gamma by the cells is measured by ELISA. They are highly specific compared with the skin test and have a similar or better sensitivity; their disadvantage is that they do not differentiate between active and latent infection.

A positive screening test, along with a review of systems, a physical examination and a chest radiograph that do not show evidence of active infection, confirms the diagnosis of latent TB. A second set of numbers for the same test goes by risk group rather than by BCG shot: >= 5 mm is positive in the immunocompromised, that is HIV and post-transplant, and in an asymptomatic person with contact of a patient with un-treated active TB; >= 10 in healthworkers; and >= 15 in the normal population. These sit beside the numbers above and the two sets do not agree, so read both. Why the blood test exists at all is written beside it: a tuberculin test can give a positive result regardless of presence of TB infection for an individual who has previously had a BCG shot, and for that reason interferon gamma release assay, a blood test, is used for screening. Mantoux test, PPD and TST are three names for the one test.

The screen is also ordered ahead of a drug rather than after an exposure. In JIA, remission is maintained on methotrexate, with liver and renal function followed, and on biologic agents, the anti-TNF drugs - and beside those biologic agents is written: do a chest x ray to rule out latent TB. So the chest film here is not for a contact or a symptom; it is the step before starting the drug that would let a latent infection go.

How it is treated

Two accounts of the regimen stand together and they do not match at every point.

One gives, for children aged 2-11 years, isoniazid 10-20 mg/kg daily or 20-40 mg/kg twice weekly for 9 months as the preferred and most efficacious treatment; the shorter 6-month course is an acceptable option for adults but is not recommended for children; and rifampin alone or in combination with isoniazid is also acceptable for adults but not for children under the age of 12.

The other gives latent TB as 3 months of rifampicin with isoniazid, or 6 months of isoniazid, and lists the indications for chemoprophylaxis: an asymptomatic contact with a positive tuberculin skin test but a normal chest X-ray; children under 16 years identified during contact tracing as having a strongly positive tuberculin test; children under 2 years in close contact with smear-positive pulmonary disease; and babies of mothers with pulmonary TB.

On pyridoxine, two lines also stand together: pyridoxine, vitamin B6, 10 mg/day is given to prevent the polyneuropathy of isoniazid; and pyridoxine is not required unless subjects are at higher risk of pyrazinamide-related peripheral neuropathy in diabetes, renal failure, HIV and alcoholics.

A third page sets the treatment out in a single line: for latent TB infection, isoniazid daily for 9 months, with no age cut-off. The alternatives it gives for adults are isoniazid plus rifapentine once weekly for 12 doses, which is 3 months, by DOT, or rifampin daily for 4 months; rifampin with pyrazinamide is not recommended there because of hepatotoxicity. So where the accounts differ over the shorter courses they agree on this one: 9 months of daily isoniazid is the preferred treatment, and the page that gives it puts no age cut-off on it.